This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
The first study of a program that uses the drug MDMA to treat post-traumatic stress disorder (PTSD) plus alcohol use disorder in military veterans has concluded with promising results.
According to the Brown University researchers who conducted the trial, the findings indicate that MDMA-assisted therapy can be safe, feasible and tolerable for participants, and they show preliminary evidence of improvement in both PTSD symptoms and alcohol-related outcomes.
"The results exceeded our expectations," said study co-author Christy Capone, an assistant professor of psychiatry and human behavior (research) at Brown University's Warren Alpert Medical School.
Capone noted that it is common for U.S. military veterans to experience both PTSD and alcohol use disorder, and the combination is associated with greater symptom severity, functional impairment and poorer outcomes than either disorder alone. Existing treatments, which include trauma-focused psychotherapies and cognitive processing therapy, demonstrate only modest effectiveness with persistent challenges in engagement, retention and sustained improvement.
There is an urgent need for novel treatment options that address both disorders and have more significant and lasting effects, Capone said.
"As a psychologist who works with military veterans, I have personally witnessed the shortcomings of the standard treatment models," Capone said. "This is an urgent matter: I am not alone among people who treat this population in losing patients to suicide because of PTSD and alcohol use disorder."
The team developed the new treatment model based on existing research demonstrating the therapeutic potential of MDMA-assisted therapy for PTSD.
Source link







